Acinetobacter baumannii ADC-25 OXA-23 OXA-66 (CDC & FDA AR Isolate Bank #0282), Peritonitis Model, LD90-100

ITEM 608860

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This model assesses the efficacy of test articles for protection against a lethal peritoneal infection with multiple-drug-resistant A. baumannii. It may be used for evaluating small molecules, vaccines, and biologics.

SPECIES

Acinetobacter baumannii

STRAIN COMMON NAME

(AR Bank #0282)

ORGANISM

Gram-negative Bacteria

INCUBATION CONDITIONS

Aerobic

GENOMIC ACCESSION NUMBER

SAMN04901672

SOURCE

STRAIN SOURCE

CDC & FDA AR Isolate Bank

STRAIN SOURCE ID

AR Bank #0282

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 10 BALB/c female mice, 7 weeks of age, weighing 18 ± 2 g, are used. Each animal is inoculated with an intraperitoneally administered LD90-100 dose (3–5 x 10³ CFU/mouse) of A. baumannii (AR Bank #0282) suspended in BHI with 5 % mucin. Vehicle and/or test substances are then administered 1 hour later per the specification of the study design table. Mortality is recorded daily during the following 7 days. Prevention of mortality is recorded in percentage and compared to the vehicle treatment group. The significance is assessed with Fisher's exact test. The mean survival time is compared to the vehicle group with Student's t-test or ANOVA.

CRITERIA FOR SIGNIFICANCE

Mortality data is graphed with the Kaplan Meier Method and Significance is assessed with the Fisher's exact test.

TURNAROUND TIME

STANDARD

20 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.